Investors Urged to Act: Class Action Against Mereo BioPharma Group plc Over Declining Stock Value

Investor Alert: Class Action Lawsuit Filed Against Mereo BioPharma

In a recent announcement, Pomerantz LLP has made it clear that a class action lawsuit has been initiated against Mereo BioPharma Group plc (NASDAQ: MREO). This development has raised alarms among investors who have suffered losses stemming from their investments in the firm.

Details of the Lawsuit

The class action centers around allegations that Mereo BioPharma and certain individuals in leadership roles may have engaged in securities fraud or other unlawful business practices. Those investors who believe they have been affected are encouraged to reach out to Pomerantz LLP to potentially be appointed as Lead Plaintiff. The deadline for filing such requests is April 6, 2026, for those who bought or acquired Mereo securities during the class period.

The Timeline of Events

On July 9, 2025, Mereo, alongside its development partner Ultragenyx Pharmaceutical Inc., released a statement on the progress of the Phase 3 study of UX143 (setrusumab). This study, aimed at pediatric and young adult patients with osteogenesis imperfecta, was anticipated to reach a final analysis by the end of the year. Following this announcement, Mereo’s ADR price plummeted by $1.25, or 42.52%, indicating investor concern.

The situation worsened on December 29, 2025, when Mereo revealed that neither the Orbit nor the Cosmic Phase 3 trials achieved statistical significance, failing to meet their primary endpoints. Following this news, the ADR price fell drastically, losing $2.02 or 87.7%, closing at a mere $0.29 per ADR. This drastic decline underscores the potential gravity of the alleged misrepresentations made by the company.

Pomerantz LLP: A Leader in Class Action Law

Pomerantz LLP, known for its significant history in corporate, securities, and antitrust class litigation, has been advocating for investors’ rights for over 85 years. With a commitment to fighting for justice, the firm has successfully recovered substantial damages in numerous cases. This class action against Mereo BioPharma is part of their ongoing efforts to hold corporations accountable for their practices and to seek restitution for affected investors.

For investors who have incurred losses related to Mereo BioPharma Group plc, it’s crucial to act promptly. Pomerantz LLP recommends that anyone interested in joining the class action contact them directly while providing pertinent information such as their mailing address, phone number, and the quantity of shares they owned.

Conclusion

Investors are reminded that time is of the essence in such cases. With the potential for class action status, the affected parties are encouraged to stand up for their rights and seek justice together. The allegations against Mereo BioPharma underscore the need for vigilance in the investment landscape and awareness of the responsibilities companies have to their shareholders.

For more updated information regarding this class action lawsuit and resources on how to participate, investors can visit Pomerantz LLP’s website.